MARK4 and central nervous system cancer: MARK4 is reportedly upregulated in liver cancer, gliomas, and glioblastomas47,48; however, the LKB1–MARK4 axis is reported to function as both an agonist and antagonist of Hippo signaling, suggesting cell-type dependent regulation of the LKB1–MARK4 axis37,49.